Tian Medicine shares proposed to raise more than 550 million major shareholders injected into the raw drug assets

NetEase Financial January 18 News Day medicine shares late announcement said that the number of shares to be issued not more than 66.5 million shares (including the number), the issue of 8.27 yuan/shares, the total amount of fund-raising not more than 550 million yuan. The announcement indicated that the day medicine shares this issue is to include the holding shareholder pharmaceutical group and so on no more than 10 specific investors, all the issuers in cash to subscribe to this private issue of shares.　　Among them, the controlling shareholder Tianjin Pharmaceutical Group Co., Ltd. intends to subscribe for this non-public offering in cash, with a subscription rate of 46.8% per cent of this private offering.　　The Non-public offering raises funds to invest in the following three projects: the acquisition of Tianjin Tian ' an Pharmaceutical Co., Ltd. amino acid raw materials business and related assets and liabilities; acquisition of Tianjin Jin Yao Biotechnology Co., Ltd. Sewage Treatment environmental Protection project assets; technical upgrading and expansion of corticosteroid drugs. Tian Medicine shares said, the release is completed, the company will add amino acid raw drug business.　　The company's controlling shareholder's raw material drug assets have realized the whole listing, is advantageous to the company to integrate the raw drug business, reduces the cost through the synergy effect, and has used the company long time the management experience as well as the operation, the sale, the brand and so on the raw material medicine business competitiveness and the profitability. Wanguo Analysis of the article pointed out that the change in the management of days of medicine shares, operating efficiency. In addition, the price of corticosteroid products rebounded, the company's market share expanded.　　It is expected that the company's full-year results may exceed expectations, EPS is expected to be 0.18-0.2 yuan. The pharmaceutical group currently holds a 46.8% per cent stake in the pharmaceutical company and is a controlling shareholder. In this private issue, the pharmaceutical group intends to subscribe to 46.8% of the shares in this private offering.　　After the Non-public release, pharmaceutical group is still in the holding position, Tianjin Sasac is still the actual control of the days medicine shares, this issue will not lead to the change of control of the days of medicine shares. As of January 11, the closing day, days of drug shares reported 9.62 Yuan, Rose 3%.